吴一龙：改写全球肺癌指南的中国医生

TL;DR - A profile of Guangdong Provincial People's Hospital oncologist Wu Yilong, awarded the 7th "Taishan Award" for clinical medical research, whose lung-cancer trials have been written into 27 treatment guidelines across 15 countries/regions. It matters as a case study of how China moved from follower to standard-setter in precision oncology — and where AI is being eyed next.

• Established EGFR-mutation-guided targeted therapy: his cohort work found ~30% EGFR mutation rate in Chinese NSCLC patients vs <10% in Western populations, and the 2009 IPASS trial (NEJM) showed gefitinib extended PFS to 9.5 months in mutation carriers, cementing the "test first, then treat" principle.
• A sustained trial pipeline moved targeted agents from advanced to adjuvant settings: ADJUVANT (2011), CheckMate-078 (2015, PD-1), ADAURA (2020, osimertinib, 51% lower post-op death risk), ALINA (2024, alectinib, 76% lower recurrence risk), LIBRETTO-432 (2026, selpercatinib, 83% lower recurrence/death risk in RET-fusion disease).
• Scale and infrastructure: 16 global-lead international trials, 110+ domestic multicenter trials, and the CTONG consortium (founded 2007) grown from 11 to 40+ sites with ~10,000 enrolled patients; a 2023 Nature Medicine "loose-eligibility" trial is cited as an early patient-centered design.
• Forward-looking AI angle is aspirational, not a result: the article states he is exploring how to apply artificial intelligence to find the next breakthrough in precision lung-cancer treatment, with no specific models or findings described.